Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Liu

Showing results (251-260 of 361) with videos related to

Pageof 37
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family OncogenesAdriana Estrada-Bernal, Anh T Le, Andrea E Doak, et al.
Lung Cancer (Amsterdam, Netherlands)|September 6, 2024
Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histologyJennifer A Marks, Nishant Gandhi, Balazs Halmos, et al.
The Oncologist|February 15, 2017
Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary CancersBenjamin A Weinberg, Kyle Gowen, Thomas K Lee, et al.
Physical Biology|December 1, 2012
Genomic analysis and selected molecular pathways in rare cancersStephen V Liu, Elizabeth Lenkiewicz, Lisa Evers, et al.
Nature|October 28, 2011
Structure and reactivity of a mononuclear non-haem iron(III)-peroxo complexJaeheung Cho, Sujin Jeon, Samuel A Wilson, et al.
Science Advances|October 1, 2021
Pseudogene-mediated DNA demethylation leads to oncogene activationJunsu Kwon, Yanjing V Liu, Chong Gao, et al.
European Journal of Cancer (Oxford, England : 1990)|July 28, 2018
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancerStephen V Liu, D Ross Camidge, Scott N Gettinger, et al.
Therapeutic Advances in Medical Oncology|November 10, 2025
Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in <i>STK11, KEAP1</i>, or <i>KRAS</i>: the TRITON studyFerdinandos Skoulidis, Hossein Borghaei, Edward B Garon, et al.
The Lancet. Oncology|February 4, 2018
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 studyGiuseppe Giaccone, Chul Kim, Jillian Thompson, et al.
Journal of the American Chemical Society|May 2, 2017
Peroxide Activation for Electrophilic Reactivity by the Binuclear Non-heme Iron Enzyme AurFKiyoung Park, Ning Li, Yeonju Kwak, et al.
Pageof 37

Showing results (251-260 of 361) with videos related to

Sort By:
Pageof 37
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 23, 2020
Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family OncogenesAdriana Estrada-Bernal, Anh T Le, Andrea E Doak, et al.
Lung Cancer (Amsterdam, Netherlands)|September 6, 2024
Molecular profiling METex14+ non-small cell lung cancer (NSCLC): Impact of histologyJennifer A Marks, Nishant Gandhi, Balazs Halmos, et al.
The Oncologist|February 15, 2017
Comprehensive Genomic Profiling Aids in Distinguishing Metastatic Recurrence from Second Primary CancersBenjamin A Weinberg, Kyle Gowen, Thomas K Lee, et al.
Physical Biology|December 1, 2012
Genomic analysis and selected molecular pathways in rare cancersStephen V Liu, Elizabeth Lenkiewicz, Lisa Evers, et al.
Nature|October 28, 2011
Structure and reactivity of a mononuclear non-haem iron(III)-peroxo complexJaeheung Cho, Sujin Jeon, Samuel A Wilson, et al.
Science Advances|October 1, 2021
Pseudogene-mediated DNA demethylation leads to oncogene activationJunsu Kwon, Yanjing V Liu, Chong Gao, et al.
European Journal of Cancer (Oxford, England : 1990)|July 28, 2018
Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancerStephen V Liu, D Ross Camidge, Scott N Gettinger, et al.
Therapeutic Advances in Medical Oncology|November 10, 2025
Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in <i>STK11, KEAP1</i>, or <i>KRAS</i>: the TRITON studyFerdinandos Skoulidis, Hossein Borghaei, Edward B Garon, et al.
The Lancet. Oncology|February 4, 2018
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 studyGiuseppe Giaccone, Chul Kim, Jillian Thompson, et al.
Journal of the American Chemical Society|May 2, 2017
Peroxide Activation for Electrophilic Reactivity by the Binuclear Non-heme Iron Enzyme AurFKiyoung Park, Ning Li, Yeonju Kwak, et al.
Pageof 37